Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CKPT POWR Grades
- Sentiment is the dimension where CKPT ranks best; there it ranks ahead of 74.1% of US stocks.
- CKPT's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- CKPT's current lowest rank is in the Stability metric (where it is better than 9.44% of US stocks).
CKPT Stock Summary
- The ratio of debt to operating expenses for Checkpoint Therapeutics Inc is higher than it is for about just 0.49% of US stocks.
- CKPT's price/sales ratio is 1,050.64; that's higher than the P/S ratio of 99.29% of US stocks.
- As for revenue growth, note that CKPT's revenue has grown -78.92% over the past 12 months; that beats the revenue growth of merely 2.07% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Checkpoint Therapeutics Inc are ARDS, SVRA, GERN, BLCM, and GLYC.
- Visit CKPT's SEC page to see the company's official filings. To visit the company's web site, go to www.checkpointtx.com.
CKPT Valuation Summary
- In comparison to the median Healthcare stock, CKPT's price/sales ratio is 25118.42% higher, now standing at 958.3.
- CKPT's price/sales ratio has moved up 860.2 over the prior 51 months.
- CKPT's price/sales ratio has moved up 860.2 over the prior 51 months.
Below are key valuation metrics over time for CKPT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CKPT | 2021-08-31 | 958.3 | 4.7 | -8.6 | -6.5 |
| CKPT | 2021-08-30 | 940.6 | 4.6 | -8.5 | -6.4 |
| CKPT | 2021-08-27 | 901.8 | 4.4 | -8.1 | -6.0 |
| CKPT | 2021-08-26 | 880.9 | 4.3 | -8.0 | -5.8 |
| CKPT | 2021-08-25 | 883.8 | 4.3 | -8.0 | -5.9 |
| CKPT | 2021-08-24 | 857.2 | 4.2 | -7.7 | -5.6 |
CKPT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CKPT has a Quality Grade of D, ranking ahead of 21.66% of graded US stocks.
- CKPT's asset turnover comes in at 0.005 -- ranking 407th of 677 Pharmaceutical Products stocks.
- VBIV, ARWR, and NOVN are the stocks whose asset turnover ratios are most correlated with CKPT.
The table below shows CKPT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 1 | 4.869 |
| 2021-03-31 | 0.004 | 1 | 4.383 |
| 2020-12-31 | 0.033 | 1 | 3.944 |
| 2020-09-30 | 0.037 | 1 | 3.435 |
| 2020-06-30 | 0.061 | 1 | 3.348 |
| 2020-03-31 | 0.117 | 1 | 3.498 |
CKPT Price Target
For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.80 | Average Broker Recommendation | 1.4 (Strong Buy) |
CKPT Stock Price Chart Interactive Chart >
CKPT Price/Volume Stats
| Current price | $3.53 | 52-week high | $5.38 |
| Prev. close | $3.37 | 52-week low | $2.16 |
| Day low | $3.33 | Volume | 844,500 |
| Day high | $3.58 | Avg. volume | 1,228,094 |
| 50-day MA | $2.94 | Dividend yield | N/A |
| 200-day MA | $2.99 | Market Cap | 292.08M |
Checkpoint Therapeutics, Inc. (CKPT) Company Bio
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Latest CKPT News From Around the Web
Below are the latest news stories about Checkpoint Therapeutics Inc that investors may wish to consider to help them evaluate CKPT as an investment opportunity.
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceWALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET. Checkpoint management will also partici |
Checkpoint Therapeutics to Participate in Two Upcoming Investor ConferencesWALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: |
Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Checkpoint Therapeutics Reports Second Quarter 2021 Financial ResultsNEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2021. |
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare ConferenceNEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the Ladenburg Thalmann 2021 Healthcare Conference, taking place July 13-14, 2021. The company will present a corporate update on Wednesday, July 14, 2021, at 11:30 a.m. ET and will also participate in one-on-one meetings during the confe |
CKPT Price Returns
| 1-mo | 16.50% |
| 3-mo | 19.66% |
| 6-mo | 10.31% |
| 1-year | 34.73% |
| 3-year | -1.26% |
| 5-year | N/A |
| YTD | 33.21% |
| 2020 | 54.07% |
| 2019 | -5.49% |
| 2018 | -53.09% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching CKPT
Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...